Trevi Therapeutics has launched a Phase 2b clinical trial testing therapeutic candidate Haduvio (nalbuphine extended-release tablets) for the treatment of chronic cough in people with idiopathic pulmonary fibrosis (IPF). The Phase 2b trial, CORAL (NCT05964335), plans to enroll about 160 adults with IPF and chronic cough. No…
Trevi launches Phase 2b trial of Haduvio for chronic cough
Each month, Brad Dell, the director of community content at Bionews, the parent company of this website, curates a list of special days of recognition ranging from the whimsical to causes that have special meaning to both individuals and entire communities. From the whimsical side of the December list,…
The U.S. Food and Drug Administration (FDA) has given GRI Bio the green light to conduct a Phase 2 trial of its investigational natural killer T-cell (NKT)-targeted therapy, GRI-0621, in people with idiopathic pulmonary fibrosis (IPF). With the clearance of its investigational new drug (IND) application, the company…
When people first think about disease or disability, they usually go to the physical symptoms — understandably, since they’re the most visible. But a chronic illness can affect all aspects of life. The emotional, social, mental, and financial implications can be grueling for patients, too. As a patient diagnosed…
Have you seen the Apple TV+ series “Ted Lasso“? In it, Lasso is a fictional U.S. football coach who was recruited to manage a soccer club in the U.K. He was recruited because he knew nothing of European football. The club’s owner, Rebecca Welton, wanted the team to…
This column is my 100th for Pulmonary Fibrosis News. Thank you for allowing me to share my journey with you every week. I’ve been humbled by so many of you who feel comfortable sharing your stories with me and other readers. I’ve recently returned from the Pulmonary Fibrosis…
As patients, it’s crucial to know our bodies and the care they need. Understanding the complex ways that a chronic condition like pulmonary fibrosis may affect us over time, as well as the options available to treat and manage symptoms, is important for long-term quality of life.
Certain immune cells called natural killer (NK) T-cells are present at higher numbers in the lungs of people with idiopathic pulmonary fibrosis (IPF) than in the lungs of healthy people, according to data announced by GRI Bio. Also, the more NK T-cells, the greater the number of macrophages,…
My mother passed away in the final hours of Thanksgiving Day three years ago. Just a week before that, I lost my stepsister, too. Understandably, it was a time of deep loss for me. At the time, COVID-19 was spreading at an alarming rate, so, like many others, I…
The first patient has been enrolled in a Phase 3 clinical trial of nebulized Tyvaso (treprostinil) inhalation solution for treating progressive pulmonary fibrosis (PPF), according to United Therapeutics, the therapy’s developer. Called TETON PPF (NCT05943535), the study will evaluate how safe Tyvaso is versus a placebo…
